Statin use in the secondary prevention of coronary heart disease in primary care: cohort study and comparison of inclusion and outcome with patients in randomised trials
暂无分享,去创建一个
S. Ebrahim | T. MacDonald | F. Sullivan | C. Bartlett | Li Wei | P. Davey
[1] T. MacDonald,et al. The Tayside Medicines Monitoring Unit (MEMO) , 2007 .
[2] V. Preedy,et al. Scottish Intercollegiate Guidelines Network , 2010 .
[3] M Egger,et al. The causes and effects of socio-demographic exclusions from clinical trials. , 2005, Health technology assessment.
[4] J. Slattery,et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.
[5] P. Donnan,et al. Optimal strategies for identifying patients with myocardial infarction in general practice. , 2003, Family practice.
[6] N J Wald,et al. A strategy to reduce cardiovascular disease by more than 80% , 2003, BMJ : British Medical Journal.
[7] J. Hippisley-Cox,et al. Cross sectional survey of effectiveness of lipid lowering drugs in reducing serum cholesterol concentration in patients in 17 general practices , 2003, BMJ : British Medical Journal.
[8] F. Sullivan,et al. Regional repositories, reintermediation and the new GMS contract: cardiovascular disease in Tayside. , 2003, Informatics in primary care.
[9] P. Macfarlane,et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial , 2002, The Lancet.
[10] P. Thompson,et al. Magnetic resonance imaging of left atrial thrombus , 2002, Heart.
[11] AndrewJ. S. Coats. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.
[12] Catherine Sudlow,et al. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.
[13] S. Yusuf. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .
[14] D. Wood,et al. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries , 2001, The Lancet.
[15] A. Hartz,et al. A comparison of observational studies and randomized, controlled trials , 2000, American journal of ophthalmology.
[16] L. Smeeth,et al. Commentary : DINS, PINS, and things-clinical and population perspectives on treatment effects , 2000 .
[17] A. McMunn,et al. Scottish Health Survey 1998 , 2000 .
[18] Results of the low-dose (20 mg) pravastatin GISSI Prevenzione trial in 4271 patients with recent myocardial infarction: do stopped trials contribute to overall knowledge? GISSI Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico). , 2000, Italian heart journal : official journal of the Italian Federation of Cardiology.
[19] P. Macfarlane,et al. The design of a prospective study of Pravastatin in the Elderly at Risk (PROSPER). PROSPER Study Group. PROspective Study of Pravastatin in the Elderly at Risk. , 1999, The American journal of cardiology.
[20] R. Collins,et al. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.
[21] S. Gottlieb,et al. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. , 1998, The New England journal of medicine.
[22] T. MacDonald,et al. Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: cohort study , 1997, BMJ.
[23] B. Davis,et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.
[24] A. Walker. Confounding by indication. , 1996, Epidemiology.
[25] Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) , 1994, The Lancet.
[26] V. Carstairs,et al. Deprivation and health in Scotland. , 1990, Health bulletin.